Jazz Pharmaceuticals: Q3 Results, Pipeline Cleanup, And An Unhappy FTC


  • Jazz Pharmaceuticals reported solid Q3 results and raised the full-year guidance by $50 million at the midpoint.
  • Xywav is overtaking Xyrem as the company's top-selling product, thanks in part to a strong launch in idiopathic hypersomnia.
  • Discontinuation of nabiximols is a small setback for the company and the first disappointment from the GW Pharma acquisition.
  • FTC is not happy with Xyrem's REMS patent that prevents Avadel's Lumryz from entering the market prior to June 2023.
  • Rapid deleveraging brings Jazz to a much better financial position.
  • Looking for a helping hand in the market? Members of Growth Stock Forum get exclusive ideas and guidance to navigate any climate. Learn More »
Q2 - 3rd Quarter Period write on sticky notes isolated on Office Desk. Stock market concept

syahrir maulana

The last few weeks have been interesting for Jazz Pharmaceuticals (NASDAQ:JAZZ). The company paid $50 million upfront for the option on Zymeworks’ (ZYME) zanidatamab in late October, it reported Q3 results in early November and the

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

ONeil Trader profile picture
Discovering growth and biotech stocks with significant upside potential
Former stockbroker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on growth and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection.

My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

Exclusive research: http://seekingalpha.com/author/oneil-trader/research

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Recommended For You

Comments (17)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.